TRANSGENE: Failure of TG4010 – Value remains in the technology platforms | CORPORATE | EUR3,2 vs. EUR6,5 (+62%)
TRANSGENE - CORPORATE | EUR3,2 vs. EUR6,5 (+62%)Failure of TG4010 – Value remains in the technology platforms
No additional efficacy seen with TG4010 combined with Opdivo
Next step is in H1 2020
Value still lies in the technology platforms – FV EUR3.2 vs EUR6.5
Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.